NCT05550363View on ClinicalTrials.gov

A Study to Evaluate the Efficacy and Safety of DEXYCU® for the Treatment of Ocular Pain Associated With Cataract Surgery (2)

PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

September 30, 2022

Primary Completion Date

September 30, 2023

Study Completion Date

September 30, 2023

Conditions
Cataract
Interventions
DRUG

Dexycu

103.4 mcg/mcl dexamethasone: equivalent dexamethasone dose: 517 mcg

OTHER

Placebo/Vehicle

Placebo/vehicle, 0 mcg/mcl dexamethasone: equivalent dexamethasone dose: 0 mcg

Sponsors
All Listed Sponsors
lead

EyePoint Pharmaceuticals, Inc.

INDUSTRY

NCT05550363 - A Study to Evaluate the Efficacy and Safety of DEXYCU® for the Treatment of Ocular Pain Associated With Cataract Surgery (2) | Biotech Hunter | Biotech Hunter